Head-to-head peptide comparisons breaking down mechanisms, study evidence, side effect profiles, and which compound fits which research goal.
21 articles
A triple agonist against the GLP-1 reference standard. Efficacy, evidence weight, safety characterization and availability compared, with a framework for why bigger numbers do not automatically mean better evidence.
Retatrutide adds a glucagon receptor to tirzepatide's GIP and GLP-1 targets. Mechanism comparison, honest cross-trial caveats on the -24.2% versus -20.9% figures, evidence maturity, and a decision matrix.
TB-500 is the synthetic analogue of the 17-amino acid bioactive domain of Thymosin Beta-4 (Tβ4). This comparison explains the relationship between the full protein and the fragment, whether they produce equivalent effects, and what the research shows about each form.
Matrixyl (palmitoyl peptides) and Argireline (Acetyl Hexapeptide-3) are the two most studied cosmetic peptide categories, but they work through entirely different mechanisms — collagen stimulation vs neurotransmitter inhibition. This comparison examines when each is appropriate and what the evidence shows for combination use.
Semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) are both GLP-1 receptor agonists, but semaglutide's albumin binding and DPP-IV modifications give it a 7-day half-life vs liraglutide's 13 hours — producing meaningfully different efficacy profiles in clinical trials.
NMN and NR are both NAD+ precursors that replenish declining nicotinamide adenine dinucleotide levels with aging. This comparison examines their metabolic pathways, bioavailability, clinical trial data, and which has stronger evidence for specific aging applications.
Sermorelin stimulates the pituitary to release its own GH; exogenous HGH replaces GH directly. These approaches produce fundamentally different physiological profiles — different GH patterns, different feedback mechanisms, and different risk considerations. This comparison examines the research evidence for each.
NAD+ and Epithalon are both studied for anti-aging properties, but NAD+ works through sirtuin activation and energy metabolism, while Epithalon activates telomerase and regulates circadian gene expression. This review compares their mechanisms and evidence.
Epithalon and MOTS-c are both studied in aging research but through entirely different mechanisms: Epithalon activates telomerase and restores circadian genes; MOTS-c is a mitochondria-derived peptide that activates AMPK and promotes metabolic resilience. This review compares their evidence.
Tesamorelin is FDA-approved for HIV-associated lipodystrophy with documented visceral fat reduction data; CJC-1295 (Mod GRF 1-29) is a widely researched GH-stimulating GHRH analogue without clinical approval. This review compares their pharmacology and evidence.
PT-141 (bremelanotide) and kisspeptin both increase sexual arousal in research models, but through completely different neurological pathways. PT-141 acts via melanocortin MC4R; kisspeptin acts via GPR54 in the hypothalamus to increase GnRH pulsatility.
Hexarelin and GHRP-2 are the two most potent GHSPs in terms of GH pulse amplitude, but hexarelin requires cycling due to faster receptor desensitization, and has unique cardiac research applications independent of GH. This comparison reviews the evidence.
CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29) are the same peptide backbone with fundamentally different pharmacokinetics. One produces pulsatile GH; the other produces sustained GH elevation. This comparison explains why the distinction matters enormously for research.
GHK-Cu and BPC-157 are both studied extensively for tissue repair, but they operate through entirely different mechanisms. GHK-Cu is a copper-chelating tripeptide that regulates gene expression; BPC-157 is a systemic healing peptide acting through NO, VEGF, and GH receptor pathways.
Melanotan I and Melanotan II both stimulate melanogenesis via MC1R activation, but differ in their receptor selectivity, sexual effects, and side effect profiles. This review compares the research evidence for both alpha-MSH analogues.
Selank and Semax are both nootropic peptides developed in Russia from the 1980s onward. They have distinct mechanisms — Selank is anxiolytic and serotonin/GABA-modulating; Semax is pro-cognitive and BDNF-stimulating. This comparison reviews their research profiles.
Fragment 176-191 and AOD-9604 are both derived from the C-terminal region of human growth hormone and studied for fat-burning activity. This comparison examines their structures, mechanisms, and research evidence for lipolysis.
CJC-1295 and sermorelin are both GHRH analogues that stimulate pituitary GH release, but differ in half-life, DPP-IV resistance, and whether they preserve physiological GH pulsatility. This comparison reviews the key research differences.
Ipamorelin and GHRP-6 both stimulate GH release via GHS-R1a, but GHRP-6 has a pronounced appetite-stimulating effect via motilin receptors that ipamorelin lacks. This review examines when each is the more appropriate research choice.
Ipamorelin and GHRP-2 are both ghrelin receptor agonists used to stimulate GH release, but they differ significantly in selectivity, potency, and side effect profiles. This comparison reviews the research evidence for each.
BPC-157 and TB-500 are the two most researched tissue-repair peptides. This comparison examines their distinct mechanisms, tissue targets, and what preclinical research reveals about their individual and combined effects.
Showing 21 of 21 Comparison articles